All In Biotech

Drug Trial Radar · NCT07380854

Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 338 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

338

Planned (sponsor's estimate)

Start

Feb 27, 2022

Primary completion

Feb 26, 2032

Study completion Feb 26, 2037

Sponsor

Lead sponsor
Seoul National University Bundang HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG). The main questions this study aims to answer are: • Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and new arrhythmias, in SCH patients undergoing CABG? Researchers will compare patients who take levothyroxine with those who do not. Participants will: * Be randomly assigned to either receive levothyroxine or not * Start the medication one day before surgery if assigned to the treatment group. * Have regular follow-up visits to check thyroid function and cardiovascular events for up to five years after surgery.

Conditions

  • Subclinical Hypothyroidism

Interventions

  • levothyroxineDrug

    Intervention description: Participants assigned to the LT4 group will begin receiving levothyroxine the day before CABG. The initial dose is 25 μg once daily, or 12.5 μg for participants weighing less than 60 kg. The dose will then be adjusted based on thyroid function test results to achieve target TSH levels of 0.4-2.0 μIU/mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A composite of MACE within 4months after surgeryTime frame: within 4months after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Internal Medicine, Seoul National University Bundang Hospital

    Seongnam-si, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.